Kingdon Capital Management, L.L.C. Prometheus Biosciences, Inc. Transaction History

Kingdon Capital Management, L.L.C.

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$22.39 - $38.94 $2.24 Million - $3.89 Million	-100,000 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$30.13 - $50.0 $1.47 Million - $2.43 Million	48,668 Added 94.81%	100,000 $3.78 Million
Q4 2021 Feb 14, 2022	BUY	$22.28 - $39.54 $1.14 Million - $2.03 Million	51,332 New	51,332 $2.03 Million
Q3 2021 Nov 15, 2021	SELL	$20.89 - $26.96 $173,742 - $224,226	-8,317 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$16.8 - $29.65 $532,274 - $939,400	-31,683 Reduced 79.21%	8,317 $204,000
Q1 2021 May 17, 2021	BUY	$16.51 - $25.29 $660,400 - $1.01 Million	40,000 New	40,000 $730,000

29.6K

Ticker RXDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,904,100
Description
Prometheus Biosciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of novel therapeutics and companion diagnostics products for the treatment of inflammatory bowel diseases (IBD). Its lead product includes PRA023, a humanized IgG1 monoclonal antibody (mAb), which is in Phase IIa clinical trial...

Get notified when there are updates to the investment portfolio of Kingdon Capital Management, L.L.C., based on Form 13F filings with the SEC.

Stay updated on Kingdon Capital Management, L.L.C. with notifications on news.